Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial

Crothers, Jessica W; Colgate, E. Ross; Cowan, Kelly; Dickson, Dorothy M.; Walsh, MaryClaire; Carmolli, Marya P.; Wright, Peter F.; Norton, Elizabeth B.; Kirkpatrick, Beth D.

doi:10.1016/j.vaccine.2022.03.056

Cited by 10 publications

(10 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IPV has been shown to not directly induce intestinal mucosal immunity, even with a mucosal adjuvant. Initial attempts to use a mucosal adjuvant (dmLT-double-mutant heat labile E Coli toxin) to induce mucosal immunity after IPV vaccination were unsuccessful [ 17 , 18 ]. IPV does appear to induce pharyngeal mucosal immunity [ 19 ], although the evidence is limited.…”

Section: Increasing the Scientific Knowledge Base Of Ipvmentioning

confidence: 99%

“…In addition, in the quest to develop a poliovirus vaccine presentation that could potentially avoid the need for a cold chain, which would not require highly trained vaccinators as with IM injections and would potentially be dose-sparing (thus cost-effective) and even providing mucosal immunity, the consortium collaborates with the University of Queensland, Australia, to develop microneedle patches (MNPs) with or without the addition of including double-mutant heat-labile enterotoxin of Escherichia coli (dmLT) [ 17 , 18 , 92 ], an adjuvant that has been shown to induce mucosal immunity in other applications. S19 IPV …”

Section: Developing the Next-generation Polio Vaccinementioning

confidence: 99%

See 1 more Smart Citation

Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance

Sutter,

Eisenhawer,

Molodecky

et al. 2024

Pathogens

View full text Add to dashboard Cite

Inactivated poliovirus vaccine (IPV), available since 1955, became the first vaccine to be used to protect against poliomyelitis. While the immunogenicity of IPV to prevent paralytic poliomyelitis continues to be irrefutable, its requirement for strong containment (due to large quantities of live virus used in the manufacturing process), perceived lack of ability to induce intestinal mucosal immunity, high cost and increased complexity to administer compared to oral polio vaccine (OPV), have limited its use in the global efforts to eradicate poliomyelitis. In order to harvest the full potential of IPV, a program of work has been carried out by the Global Polio Eradication Initiative (GPEI) over the past two decades that has focused on: (1) increasing the scientific knowledge base of IPV; (2) translating new insights and evidence into programmatic action; (3) expanding the IPV manufacturing infrastructure for global demand; and (4) continuing to pursue an ambitious research program to develop more immunogenic and safer-to-produce vaccines. While the knowledge base of IPV continues to expand, further research and product development are necessary to ensure that the program priorities are met (e.g., non-infectious production through virus-like particles, non-transmissible vaccine inducing humoral and intestinal mucosal immunity and new methods for house-to-house administration through micro-needle patches and jet injectors), the discussions have largely moved from whether to how to use this vaccine most effectively. In this review, we summarize recent developments on expanding the science base of IPV and provide insight into policy development and the expansion of IPV manufacturing and production, and finally we provide an update on the current priorities.

show abstract

Section: Increasing the Scientific Knowledge Base Of Ipvmentioning

confidence: 99%

Section: Developing the Next-generation Polio Vaccinementioning

confidence: 99%

Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance

Sutter,

Eisenhawer,

Molodecky

et al. 2024

Pathogens

View full text Add to dashboard Cite

show abstract

“…fIPV adjuvated with dmLT was well tolerated and induced systemic immune responses against all three WPV serotypes in a randomised phase 1 trial. This suggests that this approach may be useful in improving the effectiveness of polio vaccination programs around the world [ 121 ].…”

Section: New Strategies To Fight Against Pvmentioning

confidence: 99%

The Fight against Poliovirus Is Not Over

et al. 2023

View full text Add to dashboard Cite

Poliovirus (PV), the virus that causes both acute poliomyelitis and post-polio syndrome, is classified within the Enterovirus C species, and there are three wild PV serotypes: WPV1, WPV2 and WPV3. The launch of the Global Polio Eradication Initiative (GPEI) in 1988 eradicated two of the three serotypes of WPV (WPV2 and WPV3). However, the endemic transmission of WPV1 persists in Afghanistan and Pakistan in 2022. There are cases of paralytic polio due to the loss of viral attenuation in the oral poliovirus vaccine (OPV), known as vaccine-derived poliovirus (VDPV). Between January 2021 and May 2023, a total of 2141 circulating VDPV (cVDPV) cases were reported in 36 countries worldwide. Because of this risk, inactivated poliovirus (IPV) is being used more widely, and attenuated PV2 has been removed from OPV formulations to obtain bivalent OPV (containing only types 1 and 3). In order to avoid the reversion of attenuated OPV strains, the new OPV, which is more stable due to genome-wide modifications, as well as sabin IPV and virus-like particle (VLP) vaccines, is being developed and offers promising solutions for eradicating WP1 and VDPV.

show abstract

“…These adjuvants include low-cost aluminum salts, oligodeoxynucleotides (ODNs), D3, chitosan, saponins, and double mutant heat-labile toxin (dmLT) [51 ▪ ,55]. A recent phase I trial demonstrated the safety and efficacy of fIPV-dmLT; however, there was no enhanced mucosal immunity in those receiving fIPV-dmLT relative to those receiving IPV alone, suggesting areas for further exploration and improvement [56].…”

Section: Current Vaccine Strategymentioning

confidence: 99%

Threat of resurgence or hope for global eradication of poliovirus?

Kim

Piamonte

Allen

et al. 2023

Current Opinion in Neurology

View full text Add to dashboard Cite

Purpose of reviewRecent outbreaks of poliomyelitis in countries that have been free of cases for decades highlight the challenges of eradicating polio in a globalized interconnected world beset with a novel viral pandemic. We provide an epidemiological update, advancements in vaccines, and amendments in public health strategy of poliomyelitis in this review.Recent findingsLast year, new cases of wild poliovirus type 1 (WPV1) were documented in regions previously documented to have eradicated WPV1 and reports of circulating vaccine-derived poliovirus type 2 (cVDPV2) and 3 (cVDPV3) in New York and Jerusalem made international headlines. Sequencing of wastewater samples from environmental surveillance revealed that the WPV1 strains were related to WPV1 lineages from endemic countries and the cVDPV2 strains from New York and Jerusalem were not only related to each other but also to environmental isolates found in London. The evidence of importation of WPV1 cases from endemic countries, and global transmission of cVDPVs justifies renewed efforts in routine vaccination programs and outbreak control measures that were interrupted by the COVID-19 pandemic. After the novel oral poliovirus vaccine type 2 (nOPV2) received emergency authorization for containment of cVDPV2 outbreaks in 2021, subsequent reduced incidence, transmission rates, and vaccine adverse events, alongside increased genetic stability of viral isolates substantiates the safety and efficacy of nOPV2. The nOPV1 and nOPV3 vaccines, against type 1 and 3 cVDPVs, and measures to increase accessibility and efficacy of inactivated poliovirus vaccine (IPV) are in development.SummaryA revised strategy utilizing more genetically stable vaccine formulations, with uninterrupted vaccination programs and continued active surveillance optimizes the prospect of global poliomyelitis eradication.

show abstract

Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial

Cited by 10 publications

References 49 publications

Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance

Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance

The Fight against Poliovirus Is Not Over

Threat of resurgence or hope for global eradication of poliovirus?

Contact Info

Product

Resources

About